Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the mechanism of action for roflumilast cream, the only phosphodiesterase-4 inhibitor approved by the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback